|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US9522191||AYTU||Modified release formulations containing drug—ion exchange resin complexes|| |
(3 years from now)
|US8062667||AYTU||Modified release formulations containing drug-ion exchange resin complexes|| |
(5 years from now)
Karbinal Er is owned by Aytu.
Karbinal Er contains Carbinoxamine Maleate.
Karbinal Er has a total of 2 drug patents out of which 0 drug patents have expired.
Karbinal Er was authorised for market use on 28 March, 2013.
Karbinal Er is available in suspension, extended release;oral dosage forms.
The generics of Karbinal Er are possible to be released after 29 March, 2029.
Market Authorisation Date: 28 March, 2013
Dosage: SUSPENSION, EXTENDED RELEASE;ORAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic